Question 1

Are retatrutide reviews and posted results evidence?

Accepted Answer

No, and the cleanest way to see why is the placebo column in the published trials. We do not collect, aggregate or republish anybody's reported experience, and no figure published on this page originates in one. A 2025 systematic review of 26 randomised trials recorded how often adverse events appeared in participants who received a dummy injection, and the range it reports is GLP-1 RA vs. placebo: 80% to 97% vs. 63% to 100%. Read the second half of that range carefully: in some trials essentially every participant assigned to placebo reported something. That comparison is what a control group exists to supply, and it is precisely what a posted account cannot contain. A report without one is not a weaker version of a trial result but a different category of statement: an accurate record of what one person noticed, with nothing available to measure it against.

Question 2

What outcomes have the retatrutide trials actually measured?

Accepted Answer

Four, and knowing which four explains why so many reasonable questions remain unanswered. The phase 2 obesity trial measured body weight, with secondary end points that included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more. The phase 3 diabetes trial measured blood sugar instead, and records that the primary endpoint was the change in HbA1c concentration from baseline to week 40. Body weight was a secondary consideration there rather than the question the trial was designed around. The third outcome is liver fat, where a substudy set out to assess mean relative change from baseline in liver fat (LF) at 24 weeks in participants who already carried at least a tenth of their liver as fat. The fourth group of outcomes belongs to late-stage trials that have published nothing. Everything else people ask about — energy, sleep, mood, appetite as somebody would describe it — was never an endpoint anywhere.

Question 3

What did the retatrutide phase 3 results show?

Accepted Answer

One phase 3 trial has published, and it investigated blood sugar in type 2 diabetes rather than body weight. It ran 40 weeks and randomised 537 adults whose diabetes was inadequately controlled by diet and exercise alone. The headline numbers are blood-sugar numbers. The mean change from baseline in HbA1c concentration was -1·69% (SE 0·11) with retatrutide 4 mg, -1·86% (0·10) with 9 mg, and -1·94% (0·08) with 12 mg, versus -0·81% (0·12) with placebo. The placebo line is the one to hold on to, because that column moved as well. Roughly four fifths of a percentage point came off in participants receiving no active compound whatsoever, which is a measure of what dietary change, clinical attention and participation in a trial accomplish by themselves. The trial's own conclusion is cautious in the same way, describing an adverse event profile consistent with molecules with GLP-1 agonist activity.

Question 4

Who were these results measured in?

Accepted Answer

This question determines how much a published average has to do with any particular reader, and it is almost never printed alongside the averages themselves. The phase 2 diabetes trial enrolled a group with a mean age 56·2 years [SD 9·7], mean duration of diabetes 8·1 years [7·0], 156 [56%] female, and 235 [84%] White. The phase 3 trial recruited a younger and earlier group, where baseline mean age was 48·8 years (SD 12·1), mean HbA1c concentration was 7·9% (SD 1·1), mean duration of diabetes was 2·5 years (SD 4·4), and mean BMI was 35·8 kg/m2 (SD 7·0). Across the wider literature the picture is similar. A 2025 systematic review of this class describes participants with a mean body mass index, 30 to 41 kg/m2; mean age, 34 to 57 years. A result measured in a particular population remains a result about that population rather than a general characteristic of the compound.

Question 5

How many people actually finished the trials?

Accepted Answer

More than most people assume, and both trials that reported it published the arithmetic. In the phase 3 diabetes trial, 490 of the 537 randomised participants were still receiving study drug at the end and 504 of them, 94%, completed the study itself. The earlier phase 2 diabetes trial ran lower on both counts. There, 237 (84%) participants completed the study and 222 (79%) completed study treatment, which means roughly a fifth of the people who started did not finish on the compound they had been assigned. That discrepancy belongs beside every average on this page, because an average reported at a trial's conclusion describes only the participants still present to be measured. Those who discontinued are less a footnote to the result than an unreported component of it.

Question 6

What did the liver substudy measure?

Accepted Answer

It measured fat inside the liver, in a group picked for having a lot of it. Everyone came from the obesity trial, had fatty liver disease, and started with at least a tenth of the organ made up of fat. The measure is a scan rather than a symptom. Nobody in the substudy was asked how they felt, so no result from it describes anything a person would notice day to day. What the investigators report is a link rather than a lone number. In those participants, LF reductions were significantly related to changes in body weight, abdominal fat and metabolic measures associated with improved insulin sensitivity and lipid metabolism. So liver fat moved with body weight rather than apart from it, which is a narrower finding than a headline percentage suggests, and it is still the only organ-level outcome published for this compound.

Question 7

What is being measured in the trials that have not reported?

Accepted Answer

Three outcomes no study among the research behind this page has published yet, and two of them have nothing to do with weight. In the late-stage programme the weight trials measure percent change in body weight, while a sleep apnea protocol measures change in Apnea-Hypopnea Index and a knee protocol scores joint pain. Apnea-Hypopnea Index counts breathing interruptions per hour of sleep. The knee score is a questionnaire filled in by the patient. Both are real measures, and neither has produced a published number for this compound. The registry lists more of the same. A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease is marked COMPLETED with no published result, and a phase 1 study of Insulin Secretion and Insulin Sensitivity is still listed as ACTIVE_NOT_RECRUITING. Completed and published are different things, and that gap is where most of this evidence sits today.

Question 8

How much of the result is fat, and how much is not?

Accepted Answer

No study among the research behind this page has published the split for retatrutide, and the class-level estimate is large enough that the omission matters. A 2024 review of this family reports that these agents cause a loss of lean mass of about 10% or about 6 kg, comparable to a decade or more of aging in the adults studied. Read what that figure is. It is a review's summary across incretin compounds rather than a measurement inside a retatrutide trial, and no published retatrutide trial has reported body composition at all. The number is the best available and it is not about this compound specifically. The same review points at what might change it, noting that supervised resistance exercise training interventions with a duration >10 weeks can elicit large increases in lean mass (∼3 kg) and strength (∼25%) in men and women. That has not been tested alongside retatrutide either.

Question 9

What results do women see?

Accepted Answer

Women made up most of the people measured, and not one published analysis reports their results separately. Those two facts sit oddly together and they are both true. The proportions are on the record. A 2025 systematic review of this class describes a pooled population that was 72% female. The phase 3 retatrutide trial randomised 537 (296 [55%] female and 241 [45%] male) participants, and the phase 2 diabetes trial counted 156 [56%] female among its 281. So the published averages are already weighted towards women, which is not the same thing as an answer about women. A result reported separately by sex would tell a reader whether the effect differs, and no such breakdown has been published for retatrutide in any trial.

Question 10

Why do posted results and trial results disagree?

Accepted Answer

Four reasons, none of which requires anybody to be dishonest. The first is the absence of a control group, which a posted account cannot possibly supply, leaving nothing for the reported change to be measured against. The second is who is being described. Trials recruit against written criteria, and the phase 2 diabetes trial took adults aged 18-75 years with type 2 diabetes who also met thresholds for blood sugar and body size. A reader outside those boundaries was never studied, and no published figure describes them. The third is the material itself. A trial participant received a known compound at a known strength, while the FDA database holds a Class II recall of a compounded retatrutide injection filed under lack of assurance of sterility. The fourth is selection. A result dramatic enough to be worth posting is by definition unrepresentative, and nobody composes an account of an uneventful eleven months.

Question 11

How strong is the evidence behind these results?

Accepted Answer

Strong for a compound nobody has approved, and still short in the ways that matter most. The trials are randomised and placebo-controlled, which puts them well above most of what this site covers. The limits are printed by the reviewers themselves. A 2025 systematic review of 26 randomised trials reports that no head-to-head RCTs were available and that heterogeneity prevented meta-analysis, so the figures were never pooled into one estimate. A 2025 review of the wider pipeline identified 53 phase 3 and phase 2 trials across the field and records that completed phase 2 trials on incretin-based therapies showed a mean percent weight loss of 7.4% to 24.2%. That last range is the honest version of every headline number. It spans most of the useful territory, it comes from different compounds in different people, and the top of it is not a prediction for anyone.

Question 12

Is retatrutide worth it?

Accepted Answer

That is a judgement about a reader's own circumstances, and it is not ours to make. What we can do is set the measured outcomes against the unmeasured ones, which is the material anybody would need to decide it themselves. Measured: body weight over 48 weeks, blood sugar over 40 weeks and liver fat over 24 weeks, all in randomised trials carrying placebo groups. Unmeasured: everything after stopping, everything beyond a year, the fat and muscle split, and anything concerning material obtained outside a trial. A 2025 systematic review names the same hole from the research end, stating that data on mortality and obesity-related complications, such as cardio-renal-metabolic events, are needed. That is the sentence a reader should weigh hardest, because it says the outcomes people actually care about have not been measured yet, rather than that they have been measured and look fine.

Retatrutide: reported results by outcome